Prior Authorization

HEALTH POLICY BRIEF — Friday, October 16

Today’s pressure point is operational evidence: CMS is asking states to maintain the daily data that keeps dual-eligible coverage aligned, while its Star…

Matt Reid

— 3 min read
Share

Executive Briefing

Today’s pressure point is operational evidence: CMS is asking states to maintain the daily data that keeps dual-eligible coverage aligned, while its Star Ratings show why aggregate quality scores deserve a harder look at appeals performance. FDA, meanwhile, has opened a short runway for clinicians to shape a rare-disease framework before the agency has written the framework itself. The practical advantage belongs to whoever supplies concrete measures early—before administrative machinery turns assumptions into policy.

Search Scope

  • Physician practice, payment, access, burden, and coverage continuity
  • Federal agencies, regulation, public inspection, and congressional oversight
  • Digital health, AI, privacy, cyber, interoperability, EHRs, and ONC implementation
  • Prior authorization, payer accountability, utilization management, and administrative simplification
  • Coding, terminology, standards, certification, and health-data infrastructure
  • Drug and device policy, rare-disease evidence, rural care, and workforce

Federal Health Policy Watch

CMS opens a data-quality window on dual-eligible coverage. CMS is seeking comment on revisions to the state technical user guide for daily Medicare-Medicaid dual-status files. The collection lists 51 respondents and 4,896 annual burden hours; comments are due December 15. The notice does not disclose the actual technical revisions or current rejection, correction-time, lag, or beneficiary-impact rates—which is precisely where the policy value sits. (CMS/Federal Register, “Agency Information Collection Activities: Proposed Collection; Comment Request,” Oct. 16, 2026 (https://www.federalregister.gov/documents/2026/10/16/2026-21150/agency-information-collection-activities-proposed-collection-comment-request))

Policy relevance: These files help coordinate Medicare and Medicaid status and Part D enrollment. Bad data can become a coverage-continuity problem long before it appears as a tidy burden estimate.

Physician policy angle: Prepare a focused review of the revised guide and supporting statement, asking for edit, rejection, correction, lag, and beneficiary-impact measures before the December 15 deadline.

FDA asks for a rare-disease framework before showing its work. FDA will hold a hybrid public meeting October 28 and accept comments through December 11 in docket FDA-2026-N-12214. The agency says the process will inform a fit-for-purpose framework for rare-disease therapy development and regulatory review, but it has not yet published a draft framework or detailed questions. (FDA/Federal Register, “Fit-for-Purpose Rare Disease Framework Initiative; Public Meeting; Request for Information and Comments,” Oct. 16, 2026 (https://www.federalregister.gov/documents/2026/10/16/2026-21142/fit-for-purpose-rare-disease-framework-initiative-public-meeting-request-for-information-and))

Policy relevance: The blank-page stage creates leverage over how FDA treats endpoints, natural-history evidence, small-population uncertainty, postmarket evidence, and access.

Physician policy angle: Coordinate specialty-society and coalition triage now and prepare a clinician-centered issue outline before the October 28 meeting.

Prior Authorization / Payer Policy / Administrative Simplification

Star Ratings sharpen the payer-accountability question during open enrollment. CMS’s 2027 ratings will affect 2028 quality bonus payments. It reports that 37% of MA-PD contracts—covering 71% of enrollment—earned four stars or more, while the timely-appeals measure declined from 4.1 to 3.9. CMS also applied appeal-data integrity checks, but the fact sheet does not identify affected contracts or explain the operational causes. Open enrollment runs October 15 through December 7. (CMS, “2027 Medicare Advantage and Part D Star Ratings,” Oct. 8, 2026 (https://www.cms.gov/files/document/fact-sheet-2027-ma-part-d-star-ratings-october-8-2026.pdf))

Policy relevance: The topline rating is the glossy brochure; appeals performance is closer to the beneficiary’s lived experience of plan accountability.

Physician policy angle: Monitor plan-level rating shifts and data-integrity reductions during open enrollment, using appeals measures—not the aggregate star share—as the accountability signal.

Policy Action Implications

  • Review CMS’s revised dual-status user guide and supporting statement; frame targeted data-quality and coverage-continuity questions for possible comment by December 15.
  • Decide before October 28 whether rare-disease specialties should participate in FDA’s meeting or supply a coordinated evidentiary-policy outline for the December 11 docket.
  • During open enrollment, compare plan-level Star Rating and appeals changes and identify any data-integrity reductions that warrant payer-accountability follow-up.

Read more